Table 3.
PEDro score
| Ackel D Elia et al., 2011 | Carneiro – Barrera et al., 2022 | Foster et al., 2009 | Jurado – Garcia et al., 2020 | Karlsen et al., 2017 | Lins – Filho et al., 2023 | Sengul et al., 2011 | Yang et al., 2018 | |
|---|---|---|---|---|---|---|---|---|
| Eligibility | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Random allocation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Concealed allocation | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Baseline comparability | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Blinded subjects | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blinded therapists | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Blinded assessors | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Outcomes for > 85% | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Intention-to-treat analysis | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Between-group comparisons | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Point and variability measures | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 7 | 8 | 10 | 6 | 9 | 7 | 9 |
1 = yes, 0 = no